New hope for sickle cell cure: drug may prevent transplant failure
NCT ID NCT07252050
Summary
This study is testing if adding a drug called ruxolitinib to a stem cell transplant can help prevent the body from rejecting the new cells, which is a major risk. It aims to improve the chance of a cure for children and young adults with severe sickle cell disease. Up to 24 participants will receive the new drug combination and be followed for two years after their transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOETIC STEM CELL TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30329, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital of Colorado
Aurora, Colorado, 80045, United States
Contact
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Contact
-
Manning Family Children's
New Orleans, Louisiana, 70118, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.